i(3)so3-galactosylceramide has been researched along with Neuronal-Ceroid-Lipofuscinoses* in 3 studies
3 other study(ies) available for i(3)so3-galactosylceramide and Neuronal-Ceroid-Lipofuscinoses
Article | Year |
---|---|
Cell cycle arrest in Batten disease lymphoblast cells.
Batten disease is an inherited neurodegenerative disorder caused by a CLN3 gene mutation. Batten disease is characterized by blindness, seizures, cognitive decline, and early death. Although apoptotic cell death is one of the pathological hallmarks of Batten disease, little is known about the regulatory mechanism of apoptosis in this disease. Since the CLN3 gene is suggested to be involved in the cell cycle in a yeast model, we investigated the cell cycle profile and its regulatory factors in lymphoblast cells from Batten disease patients. We found G1/G0 cell cycle arrest in Batten disease cells, with overexpression of p21, sphingosine, glucosylceramide, and sulfatide as possible cell cycle regulators. Topics: Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Glucosylceramides; Humans; Membrane Glycoproteins; Molecular Chaperones; Neuronal Ceroid-Lipofuscinoses; Sphingolipids; Sphingosine; Sulfoglycosphingolipids; Up-Regulation | 2013 |
CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.
Juvenile neuronal ceroid lipofuscinosis (JNCL) belongs to the neuronal ceroid lipofuscinoses characterized by blindness/seizures/motor/cognitive decline and early death. JNCL is caused by CLN3 gene mutations that negatively modulate cell growth/apoptosis. CLN3 protein (CLN3p) localizes to Golgi/Rab4-/Rab11-positive endosomes and lipid rafts, and harbors a galactosylceramide (GalCer) lipid raft-binding domain. Goals are proving CLN3p participates in GalCer transport from Golgi to rafts, and GalCer deficits negatively affect cell growth/apoptosis. GalCer/mutant CLN3p are retained in Golgi, with CLN3p rescuing GalCer deficits in rafts. Diminishing GalCer in normal cells by GalCer synthase siRNA negatively affects cell growth/apoptosis. GalCer restores JNCL cell growth. WT CLN3p binds GalCer, but not mutant CLN3p. Sphingolipid content of rafts/Golgi is perturbed with diminished GalCer in rafts and accumulation in Golgi. CLN3-deficient raft vesicular structures are small by transmission electron microscopy, reflecting altered sphingolipid composition of rafts. CLN1/CLN2/CLN6 proteins bind to lysophosphatidic acid/sulfatide, CLN6/CLN8 proteins to GalCer, and CLN8 protein to ceramide. Sphingolipid composition/morphology of CLN1-/CLN2-/CLN6-/CLN8- and CLN9-deficient rafts are altered suggesting changes in raft structure/lipid stoichiometry could be common themes underlying these diseases. Topics: Animals; Apoptosis; Cell Line; Cell Proliferation; Cells, Cultured; Endoplasmic Reticulum; Fibroblasts; Galactosylceramides; Golgi Apparatus; Humans; Membrane Glycoproteins; Membrane Lipids; Membrane Microdomains; Membrane Proteins; Mice; Mice, Knockout; Molecular Chaperones; Mutation; Neuronal Ceroid-Lipofuscinoses; Protein Binding; Protein Transport; Subcellular Fractions; Sulfoglycosphingolipids; Tripeptidyl-Peptidase 1 | 2008 |
Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study.
Progressive epilepsy with mental retardation, EPMR, belongs to a group of inherited neurodegenerative disorders, the neuronal ceroid lipofuscinoses. The CLN8 gene that underlies EPMR encodes a novel transmembrane protein that localizes to the endoplasmic reticulum (ER) and ER-Golgi intermediate compartment. Recently, CLN8 was linked to a large eukaryotic protein family of TLC (TRAM, Lag1, CLN8) domain homologues with postulated functions in lipid synthesis, transport or sensing. By using liquid chromatography/mass spectrometry we analysed molecular species of major phosholipid and simple sphingolipid classes from cerebral samples of two EPMR patients representing a progressive and advanced state of the disease. The progressive state brain showed reduced levels of ceramide, galactosyl- and lactosylceramide and sulfatide as well as a decrease in long fatty acyl chain containing molecular species within these classes. Among glycerophospholipid classes, an increase in species containing polyunsaturated acyl chains was detected especially in phosphatidylserines and phosphatidylethanolamines. By contrast, saturated and monounsaturated species were overrepresented among phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol classes in the advanced state sample. The observed changes in brain sphingo- and phospholipid molecular profiles may result in altered membrane stability, lipid peroxidation, vesicular trafficking or neurotransmission and thus may contribute to the progression of the molecular pathogenesis of EPMR. Topics: Adult; Aged; Antigens, CD; Brain; Cholesterol; Epilepsy; Galactosylceramides; Humans; Intellectual Disability; Lactosylceramides; Male; Mass Spectrometry; Membrane Proteins; Middle Aged; Neuronal Ceroid-Lipofuscinoses; Neutral Glycosphingolipids; Phosphatidylethanolamines; Phosphatidylserines; Sphingomyelins; Sulfoglycosphingolipids | 2005 |